Bruce C Cree

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Acute inflammatory myelopathies
    Bruce A C Cree
    Department of Neurology, University of California, San Francisco, USA Electronic address
    Handb Clin Neurol 122:613-67. 2014
  2. ncbi Genetics of primary progressive multiple sclerosis
    Bruce A C Cree
    Department of Neurology, University of California, San Francisco, USA Electronic address
    Handb Clin Neurol 122:211-30. 2014
  3. ncbi Multiple sclerosis genetics
    Bruce A C Cree
    Department of Neurology, University of California, San Francisco, USA Electronic address
    Handb Clin Neurol 122:193-209. 2014
  4. doi Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis
    Bruce A C Cree
    Department of Neurology, UCSF Medical Center, USA
    Mult Scler 19:835-43. 2013
  5. doi Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data
    Bruce A C Cree
    UCSF Multiple Sclerosis Center, Department of Neurology, University of California, San Francisco, 94117, USA
    Arch Neurol 68:464-8. 2011
  6. doi Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis
    Bruce A C Cree
    Multiple Sclerosis Center at University of California, San Francisco, 94117, USA
    Ann Neurol 68:145-50. 2010
  7. pmc A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01
    Bruce A C Cree
    Department of Neurology, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 5:e11296. 2010
  8. doi Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA
    Bruce A C Cree
    Department of Neurology, University of California San Francisco, USA
    Arch Neurol 66:226-33. 2009
  9. ncbi Neuromyelitis optica: diagnosis, pathogenesis, and treatment
    Bruce Cree
    Multiple Sclerosis Center, University of California San Francisco, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA
    Curr Neurol Neurosci Rep 8:427-33. 2008
  10. ncbi Emerging monoclonal antibody therapies for multiple sclerosis
    Bruce Cree
    Multiple Sclerosis Center at UCSF, San Francisco, California 94117, USA
    Neurologist 12:171-8. 2006

Research Grants

Detail Information

Publications13

  1. ncbi Acute inflammatory myelopathies
    Bruce A C Cree
    Department of Neurology, University of California, San Francisco, USA Electronic address
    Handb Clin Neurol 122:613-67. 2014
    ..This review focuses on inflammatory spinal cord injury and its relationships with multiple sclerosis, neuromyelitis optica, acute disseminated encephalomyelitis and systemic collagen vascular and paraneoplastic diseases. ..
  2. ncbi Genetics of primary progressive multiple sclerosis
    Bruce A C Cree
    Department of Neurology, University of California, San Francisco, USA Electronic address
    Handb Clin Neurol 122:211-30. 2014
    ..International collaborative efforts could provide the means to identify such genes. Alternately, it is possible that factors other than genetics underlie the differences between these clinical phenotypes. ..
  3. ncbi Multiple sclerosis genetics
    Bruce A C Cree
    Department of Neurology, University of California, San Francisco, USA Electronic address
    Handb Clin Neurol 122:193-209. 2014
    ..Current efforts are focused on understanding how the myriad of genetic risk alleles interact within networks to influence MS risk at family level as well as within populations. ..
  4. doi Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis
    Bruce A C Cree
    Department of Neurology, UCSF Medical Center, USA
    Mult Scler 19:835-43. 2013
    ..This review assembles the most current information on the reproductive safety of approved and emerging DMTs drawn from the literature and information supplied by the manufacturers...
  5. doi Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data
    Bruce A C Cree
    UCSF Multiple Sclerosis Center, Department of Neurology, University of California, San Francisco, 94117, USA
    Arch Neurol 68:464-8. 2011
    ..Because patients of African descent may be less responsive to interferon beta treatment than patients of white race/ethnicity, the efficacy of natalizumab therapy in this population is clinically important...
  6. doi Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis
    Bruce A C Cree
    Multiple Sclerosis Center at University of California, San Francisco, 94117, USA
    Ann Neurol 68:145-50. 2010
    ..To evaluate the efficacy of 4.5mg nightly naltrexone on the quality of life of multiple sclerosis (MS) patients...
  7. pmc A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01
    Bruce A C Cree
    Department of Neurology, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 5:e11296. 2010
    ..Whether other major histocompatibility complex (MHC) genes contribute to MS susceptibility is controversial...
  8. doi Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA
    Bruce A C Cree
    Department of Neurology, University of California San Francisco, USA
    Arch Neurol 66:226-33. 2009
    ....
  9. ncbi Neuromyelitis optica: diagnosis, pathogenesis, and treatment
    Bruce Cree
    Multiple Sclerosis Center, University of California San Francisco, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA
    Curr Neurol Neurosci Rep 8:427-33. 2008
    ..This review discusses the discovery of the NMO-IgG biomarker, the identification of AQP4 as its target, the clinical applications of these advances, the pathologic implications for the anti-AQP4 antibody, and advances in NMO treatment...
  10. ncbi Emerging monoclonal antibody therapies for multiple sclerosis
    Bruce Cree
    Multiple Sclerosis Center at UCSF, San Francisco, California 94117, USA
    Neurologist 12:171-8. 2006
    ..Because of their accessibility, proteins expressed on the surface of immune system cell lineages are appealing targets for monoclonal antibody therapies...
  11. ncbi Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis
    Til Menge
    Department of Neurology, University of California San Francisco, San Francisco, CA 94143 0114, USA
    J Allergy Clin Immunol 116:453-9. 2005
    ..Galactocerebroside, the major glycolipid of central nervous system myelin, is a known target for pathogenic demyelinating antibody responses in experimental allergic encephalomyelitis (EAE), the animal model of multiple sclerosis (MS)...
  12. ncbi Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial
    Kathleen Hawker
    Department of Neurology, The Ohio State University Medical Center, Columbus, USA
    Ann Neurol 66:460-71. 2009
    ..We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks...
  13. ncbi Risk alleles for multiple sclerosis identified by a genomewide study
    David A Hafler
    Division of Molecular Immunology, Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, and Harvard Medical School, Boston, USA
    N Engl J Med 357:851-62. 2007
    ..Multiple sclerosis has a clinically significant heritable component. We conducted a genomewide association study to identify alleles associated with the risk of multiple sclerosis...

Research Grants2